New oncogenetic tests
Asper Oncogenetics portfolio has been upgraded with new tests for the risk assessment and diagnostics of colorectal cancer. Colorectal cancer tests are presented at an introductory offer, with 10% discount of the standard prices. The offer is valid until the end of 2012.
Panel of Lynch syndrome testing now includes microsatellite instability (MSI) testing, MMR protein (MLH1, MSH2, MSH6, PMS2) expression analysis by immunohistochemistry (IHC), mutation analysis of MSH2, MLH1, MSH6, PMS2 genes and methylation analysis of MLH1, MSH2, MSH6, MSH3, MLH3 and PMS2 genes. Also, BRAF mutation V600E analysis from tumour tissue is available. In addition, Asper Biotech offers MUTYH-associated Polyposis (MAP) testing.